vs

Side-by-side financial comparison of Blue Bird Corp (BLBD) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

Blue Bird Corp is the larger business by last-quarter revenue ($333.1M vs $207.3M, roughly 1.6× Ultragenyx Pharmaceutical Inc.). Blue Bird Corp runs the higher net margin — 9.2% vs -62.0%, a 71.3% gap on every dollar of revenue. On growth, Ultragenyx Pharmaceutical Inc. posted the faster year-over-year revenue change (25.9% vs 6.1%). Blue Bird Corp produced more free cash flow last quarter ($31.1M vs $-100.8M). Over the past eight quarters, Ultragenyx Pharmaceutical Inc.'s revenue compounded faster (38.0% CAGR vs -1.9%).

The Blue Bird Corporation is an American bus manufacturer. Headquartered in Fort Valley, Georgia, the company was best known for its production of school buses. The company has also manufactured a wide variety of other bus types, including transit buses, motorhomes, and specialty vehicles such as mobile libraries and mobile police command centers.

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

BLBD vs RARE — Head-to-Head

Bigger by revenue
BLBD
BLBD
1.6× larger
BLBD
$333.1M
$207.3M
RARE
Growing faster (revenue YoY)
RARE
RARE
+19.8% gap
RARE
25.9%
6.1%
BLBD
Higher net margin
BLBD
BLBD
71.3% more per $
BLBD
9.2%
-62.0%
RARE
More free cash flow
BLBD
BLBD
$131.9M more FCF
BLBD
$31.1M
$-100.8M
RARE
Faster 2-yr revenue CAGR
RARE
RARE
Annualised
RARE
38.0%
-1.9%
BLBD

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
BLBD
BLBD
RARE
RARE
Revenue
$333.1M
$207.3M
Net Profit
$30.8M
$-128.6M
Gross Margin
21.4%
Operating Margin
11.3%
-54.7%
Net Margin
9.2%
-62.0%
Revenue YoY
6.1%
25.9%
Net Profit YoY
7.1%
3.5%
EPS (diluted)
$0.94
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BLBD
BLBD
RARE
RARE
Q4 25
$333.1M
$207.3M
Q3 25
$409.4M
$159.9M
Q2 25
$398.0M
$166.5M
Q1 25
$358.9M
$139.3M
Q4 24
$313.9M
$164.6M
Q3 24
$350.2M
$139.5M
Q2 24
$333.4M
$147.0M
Q1 24
$345.9M
$108.8M
Net Profit
BLBD
BLBD
RARE
RARE
Q4 25
$30.8M
$-128.6M
Q3 25
$36.5M
$-180.4M
Q2 25
$36.5M
$-115.0M
Q1 25
$26.0M
$-151.1M
Q4 24
$28.7M
$-133.2M
Q3 24
$24.7M
$-133.5M
Q2 24
$28.7M
$-131.6M
Q1 24
$26.0M
$-170.7M
Gross Margin
BLBD
BLBD
RARE
RARE
Q4 25
21.4%
Q3 25
21.1%
Q2 25
21.6%
Q1 25
19.7%
Q4 24
19.2%
Q3 24
17.0%
Q2 24
20.8%
Q1 24
18.4%
Operating Margin
BLBD
BLBD
RARE
RARE
Q4 25
11.3%
-54.7%
Q3 25
12.3%
-106.9%
Q2 25
12.6%
-64.8%
Q1 25
9.4%
-102.6%
Q4 24
10.5%
-74.3%
Q3 24
7.3%
-94.6%
Q2 24
11.9%
-79.1%
Q1 24
10.4%
-151.9%
Net Margin
BLBD
BLBD
RARE
RARE
Q4 25
9.2%
-62.0%
Q3 25
8.9%
-112.8%
Q2 25
9.2%
-69.0%
Q1 25
7.3%
-108.5%
Q4 24
9.2%
-80.9%
Q3 24
7.0%
-95.7%
Q2 24
8.6%
-89.5%
Q1 24
7.5%
-156.8%
EPS (diluted)
BLBD
BLBD
RARE
RARE
Q4 25
$0.94
$-1.28
Q3 25
$1.11
$-1.81
Q2 25
$1.12
$-1.17
Q1 25
$0.79
$-1.57
Q4 24
$0.86
$-1.34
Q3 24
$0.71
$-1.40
Q2 24
$0.85
$-1.52
Q1 24
$0.79
$-2.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BLBD
BLBD
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$241.7M
$421.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$271.4M
$-80.0M
Total Assets
$642.3M
$1.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BLBD
BLBD
RARE
RARE
Q4 25
$241.7M
$421.0M
Q3 25
$229.3M
$202.5M
Q2 25
$173.1M
$176.3M
Q1 25
$130.7M
$127.1M
Q4 24
$136.1M
$174.0M
Q3 24
$127.7M
$150.6M
Q2 24
$88.4M
$480.7M
Q1 24
$93.1M
$112.3M
Stockholders' Equity
BLBD
BLBD
RARE
RARE
Q4 25
$271.4M
$-80.0M
Q3 25
$255.4M
$9.2M
Q2 25
$221.8M
$151.3M
Q1 25
$190.4M
$144.2M
Q4 24
$179.7M
$255.0M
Q3 24
$159.6M
$346.8M
Q2 24
$137.3M
$432.4M
Q1 24
$105.8M
$140.3M
Total Assets
BLBD
BLBD
RARE
RARE
Q4 25
$642.3M
$1.5B
Q3 25
$625.3M
$1.2B
Q2 25
$575.5M
$1.3B
Q1 25
$543.7M
$1.3B
Q4 24
$535.2M
$1.5B
Q3 24
$524.9M
$1.5B
Q2 24
$468.1M
$1.6B
Q1 24
$456.5M
$1.3B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BLBD
BLBD
RARE
RARE
Operating Cash FlowLast quarter
$36.6M
$-99.8M
Free Cash FlowOCF − Capex
$31.1M
$-100.8M
FCF MarginFCF / Revenue
9.3%
-48.6%
Capex IntensityCapex / Revenue
1.6%
0.5%
Cash ConversionOCF / Net Profit
1.19×
TTM Free Cash FlowTrailing 4 quarters
$162.6M
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BLBD
BLBD
RARE
RARE
Q4 25
$36.6M
$-99.8M
Q3 25
$65.1M
$-91.4M
Q2 25
$56.9M
$-108.3M
Q1 25
$27.8M
$-166.5M
Q4 24
$26.4M
$-79.3M
Q3 24
$55.4M
$-67.0M
Q2 24
$989.0K
$-77.0M
Q1 24
$54.6M
$-190.7M
Free Cash Flow
BLBD
BLBD
RARE
RARE
Q4 25
$31.1M
$-100.8M
Q3 25
$60.5M
$-92.7M
Q2 25
$52.3M
$-110.7M
Q1 25
$18.7M
$-167.8M
Q4 24
$21.8M
$-79.5M
Q3 24
$50.2M
$-68.6M
Q2 24
$-3.5M
$-79.0M
Q1 24
$51.8M
$-193.9M
FCF Margin
BLBD
BLBD
RARE
RARE
Q4 25
9.3%
-48.6%
Q3 25
14.8%
-58.0%
Q2 25
13.1%
-66.5%
Q1 25
5.2%
-120.5%
Q4 24
7.0%
-48.3%
Q3 24
14.3%
-49.2%
Q2 24
-1.1%
-53.7%
Q1 24
15.0%
-178.2%
Capex Intensity
BLBD
BLBD
RARE
RARE
Q4 25
1.6%
0.5%
Q3 25
1.1%
0.8%
Q2 25
1.2%
1.5%
Q1 25
2.5%
1.0%
Q4 24
1.5%
0.1%
Q3 24
1.5%
1.2%
Q2 24
1.3%
1.4%
Q1 24
0.8%
3.0%
Cash Conversion
BLBD
BLBD
RARE
RARE
Q4 25
1.19×
Q3 25
1.78×
Q2 25
1.56×
Q1 25
1.07×
Q4 24
0.92×
Q3 24
2.24×
Q2 24
0.03×
Q1 24
2.10×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BLBD
BLBD

Alternative Fuel Buses$151.4M45%
Diesel Buses$144.9M43%
Parts$24.8M7%
Other$12.1M4%

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons